Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) saw a large increase in short interest in the month of October. As of October 30th, there was short interest totaling 585,071 shares, an increase of 120.4% from the October 15th total of 265,423 shares. Approximately 4.8% of the shares of the company are sold short. Based on an average daily volume of 1,925,065 shares, the days-to-cover ratio is presently 0.3 days.
Hedge Funds Weigh In On Fractyl Health
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Fractyl Health in the second quarter valued at approximately $1,431,000. Bank of America Corp DE bought a new position in Fractyl Health during the 2nd quarter worth approximately $4,791,000. General Catalyst Group Management LLC bought a new position in Fractyl Health during the 2nd quarter worth approximately $3,880,000. Pale Fire Capital SE raised its holdings in Fractyl Health by 84.5% during the 1st quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock worth $2,711,000 after purchasing an additional 2,711,103 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in shares of Fractyl Health in the 2nd quarter worth approximately $8,968,058.
Analysts Set New Price Targets
GUTS has been the subject of a number of research reports. Morgan Stanley cut their target price on shares of Fractyl Health to $4.00 and set an “equal weight” rating for the company in a research note on Monday, October 19th. Weiss Ratings lowered shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Wall Street Zen cut shares of Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Craig Hallum set a $5.00 price objective on shares of Fractyl Health in a research report on Monday, October 19th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Fractyl Health currently has a consensus rating of “Hold” and a consensus price target of $50.25.
Read Our Latest Analysis on Fractyl Health
Fractyl Health Stock Performance
NASDAQ:GUTS opened at $0.90 on Monday. The stock’s 50-day simple moving average is $3.89 and its 200 day simple moving average is $6.87. The firm has a market capitalization of $11.98 million, a PE ratio of -0.29 and a beta of 2.91. The company has a quick ratio of 1.98, a current ratio of 1.98 and a debt-to-equity ratio of 1.41. Fractyl Health has a twelve month low of $0.80 and a twelve month high of $29.34.
Fractyl Health (NASDAQ:GUTS – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.43. On average, analysts anticipate that Fractyl Health will post -5.88 EPS for the current fiscal year.
Fractyl Health Company Profile
Fractyl Health is a clinical-stage therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company is based in Burlington, Massachusetts. Its lead program, Revita, is an investigational endoscopic procedure designed to resurface the lining of the duodenum, the first part of the small intestine. Fractyl is studying whether this approach can improve metabolic function and provide lasting benefits for people with type 2 diabetes. The company is also developing Rejuva, an experimental gene therapy platform intended to address obesity and related metabolic conditions.
See Also
- Five stocks we like better than Fractyl Health
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
